Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D2 Dopamine Receptor

Molecular Pharmacology(2021)10.1124/molpharm.121.000336Source: DataRank Database

Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D2 Dopamine Receptor is a research paper published in Molecular Pharmacology (2021). On theSindex it has a DataRank of 0. It has been cited 40 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access40 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)OA: bronzeTopics (51)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Caroline A. Cuoco,Bing Xie ORCID,Yoon Namkung ORCID,Varun V. Prabhu,Blair K. A. Willette ORCID

Live enrichment

PubMed:34353882

Fundação para a Ciência e a Tecnologia, I.P.

Grant: PTDC/CCI-BIO/29266/2017

Deep Drug Discovery and Deployment

Intramural NIH HHS

Grant: ZIA DA000609

Intramural NIH HHS

Grant: ZIA NS002263

bronzeLicense: Elsevier TDM

publisherhttps://molpharm.aspetjournals.org/content/molpharm/100/4/372.full.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0026895X2401191X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0026895X2401191X?httpAccept=text/plain

publisherhttps://syndication.highwire.org/content/doi/10.1124/molpharm.121.000336

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8626643

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciencesAllosteric RegulationAnimalsAntineoplastic AgentsCHO CellsCricetinaeCricetulusDopamine D2 Receptor AntagonistsDose-Response Relationship, DrugHEK293 CellsHumansImidazolesProtein BindingProtein Structure, SecondaryPyridinesPyrimidinesReceptors, Dopamine D2

MeSH Terms

Allosteric RegulationAnimalsAntineoplastic AgentsCHO CellsCricetinaeCricetulusDopamine D2 Receptor AntagonistsDose-Response Relationship, DrugHEK293 CellsHumansImidazolesProtein BindingProtein Structure, SecondaryPyridinesPyrimidinesReceptors, Dopamine D2

Keywords

Dose-Response Relationship, DrugPyridinesReceptors, Dopamine D2ImidazolesAntineoplastic AgentsCHO CellsProtein Structure, SecondaryDopamine D2 Receptor AntagonistsCricetulusHEK293 CellsPyrimidinesAllosteric RegulationCricetinaeAnimalsHumansProtein Binding

Sustainable Development Goals

SDG 3: 3. Good health